Neurosarcoidosis, Coccidioidomycosis, or Both!

References

• Bathla G, Freeman CW, Moritani T, et al. Retrospective, dual-centre review of imaging findings in neurosarcoidosis at presentation: prevalence and imaging sub-types. Clin Radiol. 2020;75(10):796.e791–796.e799. doi:10.1016/j.crad.2020.05.008
   Web of Science ®Google Scholar
• Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182(2):289–295. doi:10.2214/ajr.182.2.1820289
   PubMed Web of Science ®Google Scholar
• Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–1553. doi:10.1001/jamaneurol.2018.2295
   PubMed Web of Science ®Google Scholar
• Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3(7):397–407. doi:10.1016/S1474-4422(04)00805-1
   PubMed Web of Science ®Google Scholar
• Lacomis D. Neurosarcoidosis. Curr Neuropharmacol. 2011;9(3):429–436. doi:10.2174/157015911796557975
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis--diagnosis and management. Qjm. 1999;92(2):103–117. doi:10.1093/qjmed/92.2.103
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology. 2014;82(15):1307–1313. doi:10.1212/WNL.0000000000000318
   PubMed Web of Science ®Google Scholar
• Nguyen JT, Green A, Wilson MR, DeRisi JL, Gundling K. Neurologic Complications of Common Variable Immunodeficiency. J Clin Immunol. 2016;36(8):793–800. doi:10.1007/s10875-016-0336-8
   PubMed Web of Science ®Google Scholar
• Johnson RH, Sharma R, Kuran R, Fong I, Heidari A. Coccidioidomycosis: a review. J Investig Med. 2021;69(2):316–323. doi:10.1136/jim-2020-001655
   PubMed Web of Science ®Google Scholar
• Kuberski T, Yourison I. Coccidioidomycosis A Cause of Sarcoidosis. Open Forum Infect Dis. 2017;4(3):ofw117. doi:10.1093/ofid/ofw117
   PubMed Web of Science ®Google Scholar
• Baldwin KJ, Zunt JR. Evaluation and treatment of chronic meningitis. Neurohospitalist. 2014;4(4):185–195. doi:10.1177/1941874414528940
   PubMedGoogle Scholar
• Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–755. doi:10.1164/ajrccm.160.2.ats4-99
   PubMedGoogle Scholar
• Vettiyil B, Gupta N, Kumar R. Positron emission tomography imaging in sarcoidosis. World J Nucl Med. 2013;12(3):82–86. doi:10.4103/1450-1147.136731
   PubMedGoogle Scholar
• Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933–941. doi:10.1007/s00259-007-0650-8
   PubMed Web of Science ®Google Scholar
• Kim HR, Lee KH, Park SJ, et al. Anti-cancer activity and mechanistic features of a NK cell activating molecule. Cancer Immunol Immunother. 2009;58(10):1691–1700. doi:10.1007/s00262-009-0680-0
   PubMed Web of Science ®Google Scholar
• Wang Y, Andrews J, Jenkins Colon P, Wundes A. FDG-PET abnormalities leading to the diagnosis of an unusual case of probable neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e506. doi:10.1212/NXI.0000000000000506
   PubMed Web of Science ®Google Scholar
• Akaike G, Itani M, Shah H, et al. PET/CT in the Diagnosis and Workup of Sarcoidosis: focus on Atypical Manifestations. Radiographics. 2018;38(5):1536–1549. doi:10.1148/rg.2018180053
   PubMed Web of Science ®Google Scholar
• Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. Neurology Neuroimmunology Neuroinflammation. 2021;8(6). doi:10.1212/NXI.0000000000001084
   PubMed Web of Science ®Google Scholar
• Judson MA. Corticosteroids in sarcoidosis. Rheumatic Dis Clin. 2016;42(1):119–135. doi:10.1016/j.rdc.2015.08.012
   PubMed Web of Science ®Google Scholar
• Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220. doi:10.1186/s12883-016-0741-x
   PubMed Web of Science ®Google Scholar
• Anthony J, Esper GJ, Ioachimescu A. Hypothalamic–pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review. Pituitary. 2016;19(1):19–29. doi:10.1007/s11102-015-0678-x
   PubMed Web of Science ®Google Scholar
• Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. J Neurol. 2015;262(2):258–267. doi:10.1007/s00415-014-7482-9
   PubMed Web of Science ®Google Scholar
• West SG. Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations. Curr Opinion Rheumatol. 2018;30(3):243–248. doi:10.1097/BOR.0000000000000489
   PubMed Web of Science ®Google Scholar
• Garoon RB, Foroozan R, Vaphiades MS. Don’t drink in The Valley. Surv Ophthalmol. 2017;62(3):383–386. doi:10.1016/j.survophthal.2016.04.002
   PubMed Web of Science ®Google Scholar
• Sharma OP, Arora A. Coccidioidomycosis and sarcoidosis. Multiple recurrences. West J Med. 1997;166(5):345–347.
   PubMedGoogle Scholar
• Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a Descriptive Survey of a Reemerging Disease. Clinical Characteristics and Current Controversies. Medicine. 2004;83(3):149–175. doi:10.1097/01.md.0000126762.91040.fd
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(10):1418–1422. doi:10.1136/bjophthalmol-2018-313356
   PubMed Web of Science ®Google Scholar
• Van Dyke MCC, Thompson GR, Galgiani JN, Barker BM. The Rise of Coccidioides: forces Against the Dust Devil Unleashed. Front Immunol. 2019;10:2188. doi:10.3389/fimmu.2019.02188
   PubMed Web of Science ®Google Scholar
• Grunewald J, Eklund A. Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc. 2007;4(5):461–464. doi:10.1513/pats.200606-130MS
   PubMedGoogle Scholar
• Baughman RP, Hurtubise PE. Systemic immune response of patients with active pulmonary sarcoidosis. Clin Exp Immunol. 1985;61(3):535–541.
   PubMed Web of Science ®Google Scholar
• Bacharach T, Zalis EG. Sarcoid Syndrome Associated With Coccidioidomycosis. Am Rev Respir Dis. 1963;88:248–251. doi:10.1164/arrd.1963.88.2.248
   PubMedGoogle Scholar
• Ellis FW. Coexistent arrested disseminated coccidioidomycosis and Boeck’s sarcoid. Calif Med. 1955;82(5):400–404.
   PubMedGoogle Scholar
• Lord G. Pulmonary sarcoidosis complicated by cryptococcosis and coccidioidomycosis. The changing spectrum of fungus disease in Maine. J Maine Med Assoc. 1974;65(10):236–240.
   PubMedGoogle Scholar
• Lipschultz BM, Liston HE. Steroid induced disseminated coccidioidomycosis: report of two cases. Dis Chest. 1964;46(3):355–359. doi:10.1378/chest.46.3.355
   PubMedGoogle Scholar
• Shewry S Epidemiologic Summary Of Valley Fever (Coccidioidomycosis) In California; 2019. Available form: https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CocciEpiSummary2019.pdf. Accessed December 20, 2023.
   Google Scholar
• Yang L, Yang M, Li S, Zhao Z. S-allylmercaptocysteine attenuates posaconazole-induced adverse effects in mice through antioxidation and anti-inflammation. Int Immunopharmacol. 2018;58:9–14. doi:10.1016/j.intimp.2018.03.006
   PubMed Web of Science ®Google Scholar